Treatment Choice in Primary Dysmenorrhea

• Status: Completed
• Trial end date: 2016-10-10
• Target enrollment: 0
• Participant gender: Female

Summary

Our aim is to evaluate and compare the pain relief of estradiol valerate/dienogest and ethinylestradiol/ drospirenone by using doppler indices.

100 nullipara patients with symptoms of severe primary dysmenorrhea (PD) requesting contraception aged from 18 to 35 were included to the study. Visual analog scale (VAS), the uterine artery doppler indices including systole/diastole rates ( S/D), pulsatility index (PI) and resistance index (RI) values were evaluated and recorded in both uterine vessels before treatment. The 66 PD patients who met the inclusion criteria were divided into 2 groups and 33 healthy controls created Group 1. Group 2 were administered estradiol valerate/dienogest while Group 3 were administered 0.03 mg ethinylestradiol and 3 mg drospirenone. Both VAS scores and doppler indices were repeated after 3 months treatment. The changes in values were recorded.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Adana Numune Training and Research Hospital
• Treatments: Dienogest; Drospirenone; Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Ethinyl Estradiol; Nandrolone; Polyestradiol phosphate

Criteria

Inclusion Criteria:

• must be nullipara patients with symptoms of severe primary dysmenorrhea.

• The characteristic of pain must be periodic (at least following 3 menstrual cycles),

• midline,

• lower abdominal cramps or pelvic colic like pain that starts up to one day before menses,

• lasts for the 3 days of bleeding,

• gradually diminishes over 12 to 72 hours,

• ends after period.

• The pain must start generally in 2 to 3 years after menarche with regular menses (25-31 day).

Exclusion Criteria:

• Patients with history of pelvic inflammatory diseases,

• endometriosis,

• ovarian cysts,

• chronic abdominal pain,

• fibroids,

• obstructive endometrial polyps,

• cervical stenosis,

• inflammatory bowel syndrome,

• irritable bowel syndrome,

• major abdominal or pelvic surgery,

• intrauterine device,

• congenital obstructive müllerian malformations.

• patients that OCP treatment was contraindicated

• patients enrolled simultaneously into other studies that require drug intake or otherwise prevent compliance with protocol.